|
1
|
Leung DYL, Lee CT, Chu SYJ, Ng F, Wen P, Fan J, Cheung DSK, Seto Nielsen L, Guruge S, Wong J. Chinese family care partners of older adults in Canada have grit: A qualitative study. J Adv Nurs 2024; 80:1018-1029. [PMID: 37828729 DOI: 10.1111/jan.15878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 08/03/2023] [Accepted: 09/11/2023] [Indexed: 10/14/2023]
Abstract
AIM To explain the process taken by Chinese family care partners of older adults in the Greater Toronto Area, Canada, to access health and social services in their communities. The research question was: What mechanisms and structures impact the agency of Chinese family care partners of older adults, in the process of assisting them to access health and social services? DESIGN This qualitative study was informed by critical realism. METHODS Chinese family care partners of older adults in the Greater Toronto Area, Canada, were interviewed from August 2020 to June 2021. Transcripts underwent thematic analysis. FINDINGS Twenty-eight Chinese family care partners expressed a firm commitment to maintain caregiving conditions and to judiciously access health and social services. Their commitment was made up of three parts: (a) legislative and cultural norms of family, work, and society; (b) their perseverance to fill gaps with limited social and financial resources; (c) the quality of their relationship to, and illness trajectory of the older adults. The social structures created tension in how Chinese family care partners made decisions, negotiated resources, and ultimately monitored and coordinated timely access with older adults. CONCLUSION Participants' commitment and perseverance were conceptualized as "grit," central to their agency to conform to legislative and cultural norms. Moreover, findings support grit's power to motivate and sustain family caregiving, in order for older adults to age in place as long as possible with finite resources. IMPLICATIONS FOR THE PROFESSION This study highlights the importance of cultural awareness education for nurses, enabling continuity of care at a systems level and for a more resilient healthcare system. IMPACT Family care partners' grit may be crucial for nurses to harness when together, they face limited access to culturally appropriate health and social services in a system grounded in values of equity and inclusion, as in Canada. REPORTING METHOD When writing this manuscript, we adhered to relevant EQUATOR guidelines of the Consolidated Criteria for Reporting Qualitative Research (COREQ). PATIENT OR PUBLIC INVOLVEMENT AND ENGAGEMENT No patient or public involvement.
Collapse
Affiliation(s)
- D Y L Leung
- School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
| | - C T Lee
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - S Y J Chu
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - F Ng
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - P Wen
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - J Fan
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - D S K Cheung
- School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
| | - L Seto Nielsen
- School of Nursing, York University, Toronto, Ontario, Canada
| | - S Guruge
- Daphne Cockwell School of Nursing, Toronto Metropolitan University, Toronto, Ontario, Canada
| | - J Wong
- Stronach Regional Cancer Centre at Southlake, Newmarket, Ontario, Canada
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
|
2
|
Wen P, He J, Zhang Q, Qi H, Zhang A, Liu D, Sun Q, Wang Y, Li Q, Wang W, Chen Z, Wang Y, Liu Y, Wan J. SET Domain Group 703 Regulates Planthopper Resistance by Suppressing the Expression of Defense-Related Genes. Int J Mol Sci 2023; 24:13003. [PMID: 37629184 PMCID: PMC10455402 DOI: 10.3390/ijms241613003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 08/11/2023] [Accepted: 08/14/2023] [Indexed: 08/27/2023] Open
Abstract
Plant defense responses against insect pests are intricately regulated by highly complex regulatory networks. Post-translational modifications (PTMs) of histones modulate the expression of genes involved in various biological processes. However, the role of PTMs in conferring insect resistance remains unclear. Through the screening of a T-DNA insertion activation-tagged mutant collection in rice, we identified the mutant planthopper susceptible 1 (phs1), which exhibits heightened expression of SET domain group 703 (SDG703). This overexpression is associated with increased susceptibility to the small brown planthopper (SBPH), an economically significant insect pest affecting rice crops. SDG703 is constitutively expressed in multiple tissues and shows substantial upregulation in response to SBPH feeding. SDG703 demonstrates the activity of histone H3K9 methyltransferase. Transcriptomic analysis revealed the downregulation of genes involved in effector-triggered immunity (ETI) and pattern-triggered immunity (PTI) in plants overexpressing SDG703. Among the downregulated genes, the overexpression of SDG703 in plants resulted in a higher level of histone H3K9 methylation compared to control plants. Collectively, these findings indicate that SDG703 suppresses the expression of defense-related genes through the promotion of histone methylation, consequently leading to reduced resistance against SBPH. The defense-related genes regulated by histone methylation present valuable targets for developing effective pest management strategies in future studies. Furthermore, our study provides novel insight into the epigenetic regulation involved in plant-insect resistance.
Collapse
Affiliation(s)
- Peizheng Wen
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Jun He
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Qiong Zhang
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Hongzhi Qi
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Aoran Zhang
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Daoming Liu
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Quanguang Sun
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Yongsheng Wang
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Qi Li
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Wenhui Wang
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Zhanghao Chen
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Yunlong Wang
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Yuqiang Liu
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
| | - Jianmin Wan
- State Key Laboratory of Crop Genetics & Germplasm Enhancement and Utilization, Jiangsu Nanjing Rice Germplasm Resources National Field Observation and Research Station, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Nanjing 210095, China; (P.W.); (J.H.); (Q.Z.); (H.Q.); (A.Z.); (D.L.); (Q.S.); (Y.W.); (Q.L.); (W.W.); (Z.C.); (Y.W.)
- National Key Facility for Crop Gene Resources and Genetic Improvement, Institute of Crop Science, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| |
Collapse
|
|
3
|
White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. Ann Oncol 2023; 34:300-314. [PMID: 36494005 DOI: 10.1016/j.annonc.2022.11.008] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 11/14/2022] [Accepted: 11/15/2022] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND New precision medicine therapies are urgently required for glioblastoma (GBM). However, to date, efforts to subtype patients based on molecular profiles have failed to direct treatment strategies. We hypothesised that interrogation of the GBM tumour microenvironment (TME) and identification of novel TME-specific subtypes could inform new precision immunotherapy treatment strategies. MATERIALS AND METHODS A refined and validated microenvironment cell population (MCP) counter method was applied to >800 GBM patient tumours (GBM-MCP-counter). Specifically, partition around medoids (PAM) clustering of GBM-MCP-counter scores in the GLIOTRAIN discovery cohort identified three novel patient clusters, uniquely characterised by TME composition, functional orientation markers and immune checkpoint proteins. Validation was carried out in three independent GBM-RNA-seq datasets. Neoantigen, mutational and gene ontology analysis identified mutations and uniquely altered pathways across subtypes. The longitudinal Glioma Longitudinal AnalySiS (GLASS) cohort and three immunotherapy clinical trial cohorts [treatment with neoadjuvant/adjuvant anti-programmed cell death protein 1 (PD-1) or PSVRIPO] were further interrogated to assess subtype alterations between primary and recurrent tumours and to assess the utility of TME classifiers as immunotherapy biomarkers. RESULTS TMEHigh tumours (30%) displayed elevated lymphocyte, myeloid cell immune checkpoint, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 transcripts. TMEHigh/mesenchymal+ patients featured tertiary lymphoid structures. TMEMed (46%) tumours were enriched for endothelial cell gene expression profiles and displayed heterogeneous immune populations. TMELow (24%) tumours were manifest as an 'immune-desert' group. TME subtype transitions upon recurrence were identified in the longitudinal GLASS cohort. Assessment of GBM immunotherapy trial datasets revealed that TMEHigh patients receiving neoadjuvant anti-PD-1 had significantly increased overall survival (P = 0.04). Moreover, TMEHigh patients treated with adjuvant anti-PD-1 or oncolytic virus (PVSRIPO) showed a trend towards improved survival. CONCLUSIONS We have established a novel TME-based classification system for application in intracranial malignancies. TME subtypes represent canonical 'termini a quo' (starting points) to support an improved precision immunotherapy treatment approach.
Collapse
Affiliation(s)
- K White
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - K Connor
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - M Meylan
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, France
| | - A Bougoüin
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, France
| | - M Salvucci
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - F Bielle
- Paris Brain Institute (ICM), CNRS UMR 7225, Inserm U 1127, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - A C O'Farrell
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - K Sweeney
- National Centre of Neurosurgery, Beaumont Hospital, Dublin, Ireland
| | - L Weng
- VIB-KU Leuven Center for Cancer Biology, Department of Oncology, Leuven, Belgium
| | - G Bergers
- VIB-KU Leuven Center for Cancer Biology, Department of Oncology, Leuven, Belgium
| | - P Dicker
- Epidemiology & Public Health, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - D M Ashley
- Duke Cancer Institute, Duke University, Durham, USA
| | - E S Lipp
- Duke Cancer Institute, Duke University, Durham, USA
| | - J T Low
- Duke Cancer Institute, Duke University, Durham, USA
| | - J Zhao
- Department of Systems Biology at Columbia University, New York, USA
| | - P Wen
- Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - R Prins
- Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, USA
| | - M Verreault
- Paris Brain Institute (ICM), CNRS UMR 7225, Inserm U 1127, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - A Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France
| | - A Biswas
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - J H M Prehn
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - D Lambrechts
- Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium
| | - I Arijs
- Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium
| | - F Lodi
- Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium
| | - G Dilcan
- Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium
| | - M Lamfers
- Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - S Leenstra
- Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - F Fabro
- Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - I Ntafoulis
- Department of Neurosurgery, Brain Tumor Center, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - J M Kros
- Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - J Cryan
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - F Brett
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - E Quissac
- Paris Brain Institute (ICM), CNRS UMR 7225, Inserm U 1127, UPMC-P6 UMR S 1127, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - A Beausang
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - S MacNally
- National Centre of Neurosurgery, Beaumont Hospital, Dublin, Ireland
| | - P O'Halloran
- National Centre of Neurosurgery, Beaumont Hospital, Dublin, Ireland
| | - J Clerkin
- National Centre of Neurosurgery, Beaumont Hospital, Dublin, Ireland
| | - O Bacon
- Department of Neuropathology, Beaumont Hospital, Dublin, Ireland
| | - A Kremer
- Information Technology for Translational Medicine (ITTM), Luxembourg, Luxembourg
| | - R T Chi Yen
- Information Technology for Translational Medicine (ITTM), Luxembourg, Luxembourg
| | - F S Varn
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - R G W Verhaak
- The Jackson Laboratory for Genomic Medicine, Farmington, USA; Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, the Netherlands
| | - C Sautès-Fridman
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, France
| | - W H Fridman
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, Paris, France
| | - A T Byrne
- Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
| |
Collapse
|
|
4
|
Wick W, Gamelas Magalhaes J, Dos Santos Leite A, IdBaih A, Vieito Villar M, Tabatabai G, Stradella A, Ghiringhelli F, Burger M, Mildenberger I, Herrlinger U, Touat M, Wen P, Wick A, Toussaint H, Gouttefangeas C, Bonny C, Paillarse JM, Reardon D. 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
|
5
|
Wick W, IdBaih A, Vieito Villar M, Tabatabai G, Stradella A, Ghiringhelli F, Burger M, Mildenberger I, Herrlinger U, Touat M, Wen P, Wick A, Gouttefangeas C, Maia A, Bonny C, Paillarse JM, Fagerberg J, Reardon D. 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
|
6
|
Weller M, Ellingson B, Alexander B, Wen P, Sulman E, Colman H, Berry D, Tanner K, Khasraw M, Lim M, Perry J, Lassman A, Cloughesy T, Yung WKA, Lee EQ, Mellinghoff I, Gordon G, de Groot J, Mikkelsen T, Cavenee W, Nelli A, Buxton M, Li W. P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform trial designed to rapidly identify experimental therapies that improve overall survival and confirm efficacious experimental therapies and associated biomarker signatures to support new drug approvals and registration. It is a collaboration between academic investigators, patient organizations and industry, under the sponsorship of the non-profit organization, Global Coalition for Adaptive Research, to support new drug applications for newly diagnosed and recurrent GBM.
Material and Methods
The primary objective of GBM AGILE is to identify therapies that effectively improve overall survival in patients with newly diagnosed or recurrent GBM. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to investigational arms based on their performance. Operating under a master protocol, GBM AGILE allows multiple drugs from different pharmaceutical companies to be evaluated simultaneously and/or over time against a common control arm. Based on performance, a drug may graduate and move to a Stage 2 (Phase 3) within the trial, and the totality of the data can be used for a new drug application and registration process. New experimental therapies are added as information about promising new drugs is identified while other therapies are removed as they complete their evaluation. The master protocol/ trial infrastructure includes efficiencies through an adaptive trial design, shared control arm and operational processes such as risk-based monitoring and enhanced remote activities. With its adaptable structure, GBM AGILE has continued trial activation, inclusion of new investigational therapies, and enrollment globally through the challenges of a global pandemic.GBM AGILE provides an efficient mechanism to screen and develop robust information regarding the efficacy of proposed novel therapeutics and associated biomarkers for GBM and to quickly move therapies and biomarkers into clinic. GBM AGILE received initial approval from the United States FDA in April 2019, and in Europe through the Voluntary Harmonization Procedure (VHP) in April, 2021. As of 2022, AGILE has screened over 1000 patients studying multiple investigational treatments. Enrollment rates are 3 to 4 times greater than traditional GBM trials, with active sites averaging 0.75 to 1 patients/site/month.
Currently, there are 41 sites activated in the US, 4 in Canada and 2 in Switzerland and an estimated 24 sites yet to open in Germany, France, Switzerland, Italy and Austria. In addition to the continued expansion in Europe, effort is undergoing to extend the trial to China and Australia as well. Clinical trial information: NCT03970447
Collapse
Affiliation(s)
- M Weller
- Universitätsspital Zürich , Klinik für Neurologie, Zürich , Switzerland
| | - B Ellingson
- University of California , Los Angeles, CA , United States
| | - B Alexander
- Dana Farber Cancer Institute, Harvard University , Boston, MA , United States
| | - P Wen
- Dana Farber Cancer Institute , Boston, MA , United States
| | - E Sulman
- NYU Grossman School of Medicine , New York, NY , United States
| | - H Colman
- University of Utah, Salt Lake City, UT , United States
| | - D Berry
- Berry Consultants , Austin, TX , United States
| | - K Tanner
- National Brain Tumor Society , Newton, MA , United States
| | - M Khasraw
- Duke Cancer Institute, Duke University , Durham, NC , United States
| | - M Lim
- Stanford University , Stanford, CA , United States
| | - J Perry
- University of Toronto, Toronto , ON , Canada
| | - A Lassman
- Columbia University, New York City, NY , United States
| | - T Cloughesy
- University of California Los Angeles , Los Angeles, CA , United States
| | - W K A Yung
- UT MD Anderson Cancer Center , Houston, TX , United States
| | - E Q Lee
- Dana Farber Cancer Institute , Boston, MA , United States
| | - I Mellinghoff
- Memorial Sloan Kettering, New York City, NY , United States
| | - G Gordon
- Global Coalition for Adaptive Research , Larkspur, CA , United States
| | - J de Groot
- University of California, San Francisco , San Francisco, CA , United States
| | - T Mikkelsen
- Henry Ford Health , Detroit, MI , United States
| | - W Cavenee
- University of California San Diego , La Jolla, CA , United States
| | - A Nelli
- Global Coalition for Adaptive Research , Larkspur, CA , United States
| | - M Buxton
- Global Coalition for Adaptive Research , Larkspur, CA , United States
| | - W Li
- Beijing Tiantan Hospital, Capital Medical University , Beijing , China
| |
Collapse
|
|
7
|
Zhang X, Liu D, Gao D, Zhao W, Du H, Qiu Z, Huang J, Wen P, Wang Y, Li Q, Wang W, Xu H, He J, Liu Y, Wan J. Cytokinin Confers Brown Planthopper Resistance by Elevating Jasmonic Acid Pathway in Rice. Int J Mol Sci 2022; 23:5946. [PMID: 35682620 PMCID: PMC9180265 DOI: 10.3390/ijms23115946] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/22/2022] [Accepted: 05/22/2022] [Indexed: 01/23/2023] Open
Abstract
Plants have evolved a sophisticated defense system that employs various hormone pathways to defend against attacks by insect pests. Cytokinin (CK) plays an important role in plant growth and stress tolerance, but the role of CKs in plant-insect interaction remains largely unclear. Here, we report that CKs act as a positive regulator in rice resistance against brown planthopper (BPH), a devastating insect pest of rice. We found that BPH feeding promotes CK biosynthesis and signaling in rice. Exogenous application of CKs significantly increased the rice resistance to BPH. Increasing endogenous CKs by knocking out cytokinin oxidase/dehydrogenase (OsCKXs) led to enhanced resistance to BPH. Moreover, the levels of the plant hormone jasmonic acid (JA) and the expression of JA-responsive genes were elevated by CK treatment and in OsCKXs knockout plants. Furthermore, JA-deficient mutant og1 was more susceptible to BPH, and CK-induced BPH resistance was suppressed in og1. These results indicate that CK-mediated BPH resistance is JA-dependent. Our findings provide the direct evidence for the novel role of CK in promoting insect resistance, and demonstrate that CK-induced insect resistance is JA-dependent. These results provide important guidance for effective pest management strategies in the future.
Collapse
Affiliation(s)
- Xiao Zhang
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Daoming Liu
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Dong Gao
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Weining Zhao
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Huaying Du
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Zeyu Qiu
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Jie Huang
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Peizheng Wen
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Yongsheng Wang
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Qi Li
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Wenhui Wang
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Haosen Xu
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Jun He
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Yuqiang Liu
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
| | - Jianmin Wan
- State Key Laboratory for Crop Genetics & Germplasm Enhancement, Jiangsu Provincial Research Center of Plant Gene Editing Engineering, Nanjing Agricultural University, Weigang 1, Nanjing 210095, China; (X.Z.); (D.L.); (D.G.); (W.Z.); (H.D.); (Z.Q.); (J.H.); (P.W.); (Y.W.); (Q.L.); (W.W.); (H.X.); (J.H.)
- National Key Facility for Crop Gene Resources and Genetic Improvement, Institute of Crop Science, Chinese Academy of Agricultural Sciences, Beijing 100081, China
| |
Collapse
|
|
8
|
Frappaz D, Dhall G, Murray MJ, Goldman S, Faure Conter C, Allen J, Kortmann R, Haas-Kogen D, Morana G, Finlay J, Nicholson JC, Bartels U, Souweidane M, Schöenberger S, Vasiljevic A, Robertson P, Albanese A, Alapetite C, Czech T, Lau CC, Wen P, Schiff D, Shaw D, Calaminus G, Bouffet E. Intracranial germ cell tumors in Adolescents and Young Adults: European and North American consensus review, current management and future development. Neuro Oncol 2021; 24:516-527. [PMID: 34724065 PMCID: PMC8972311 DOI: 10.1093/neuonc/noab252] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The incidence of intracranial germ cell tumors (iGCT) is much lower in European and North American (E&NA) than in Asian population. However, E&NA cooperative groups have simultaneously developed with success treatment strategies with specific attention paid to long-term sequelae. Neurological sequelae may be reduced by establishing a diagnosis with an endoscopic biopsy and/or cerebrospinal fluid (CSF) and/or serum analysis, deferring the need to perform a radical surgery. Depending on markers and/or histological characteristics, patients are treated as either germinoma or non-germinomatous germ cell tumors (NGGCT). Metastatic disease is defined by a positive CSF cytology and/or distant drops in craniospinal MRI. The combination of surgery and/or chemotherapy and radiation therapy is tailored according to grouping and staging. With more than 90% 5-year event-free survival (EFS), localized germinomas can be managed without aggressive surgery, and benefit from chemotherapy followed by whole ventricular irradiation with local boost. Bifocal germinomas are treated as non-metastatic entities. Metastatic germinomas may be cured with craniospinal irradiation. With a 5-year EFS over 70%, NGGCT benefit from chemotherapy followed by delayed surgery in case of residual disease, and some form of radiotherapy. Future strategies will aim at decreasing long-term side effects while preserving high cure rates.
Collapse
Affiliation(s)
- D Frappaz
- Institut d'Hématologie Oncologie Pédiatrique, Lyon, France
| | - G Dhall
- University of Alabama at Birmingham (UAB), Birmingham, USA
| | - M J Murray
- Department of Pathology, University of Cambridge, Cambridge, UK.,Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - S Goldman
- Phoenix Children's Hospital University of Arizona, USA
| | - C Faure Conter
- Institut d'Hématologie Oncologie Pédiatrique, Lyon, France
| | - J Allen
- NYU Grossman School, New York, USA
| | - R Kortmann
- University of Leipzig Medical Center; Leipzig, Germany
| | | | | | - J Finlay
- Nationwide Children's Hospital, Colombus, USA
| | - J C Nicholson
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Ute Bartels
- The Hospital for Sick Children, University of Toronto, Toronto, Canada
| | - M Souweidane
- Memorial Sloan Kettering Cancer Center, New York, USA
| | - S Schöenberger
- Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany
| | - A Vasiljevic
- Centre de Pathologie et Neuropathologie Est, Hospices Civils de Lyon, France
| | | | | | | | - T Czech
- Medical University of Vienna, Austria
| | - C C Lau
- Connecticut Children's Medical Center, USA
| | - P Wen
- University of Leipzig Medical Center; Leipzig, Germany
| | - D Schiff
- University of Virginia School of Medicine, Charlottesville, USA
| | - D Shaw
- Seattle Children's Hospital and University of Washington, Seattle USA
| | | | - E Bouffet
- The Hospital for Sick Children, University of Toronto, Toronto, Canada
| |
Collapse
|
|
9
|
Lamba N, Cagney D, Catalano P, Wen P, Haas-Kogan D, Aizer A. Predictors of Long-Term Survival Among Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
10
|
Wen P, Zhang W, Wang P, Zhang Y, Zhang W, Zhao Y, Guo H. Osteogenic effects of the peptide fraction derived from pepsin-hydrolyzed bovine lactoferrin. J Dairy Sci 2021; 104:3853-3862. [PMID: 33551166 DOI: 10.3168/jds.2020-19138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Accepted: 11/04/2020] [Indexed: 11/19/2022]
Abstract
Osteoporosis is a common disease that frequently occurs in the older population, particularly in postmenopausal women. It severely compromises the health of the older population, and the drugs commonly used to treat osteoporosis have a variety of adverse effects. Lactoferrin (LF) is a protein present in milk that has recently been found to exhibit osteogenic activity. Lactoferrin is nontoxic and harmless, suggesting that it may have excellent biocompatibility and tolerability after human consumption. Oral consumption of LF in an ovariectomized rat model has been found to ameliorate osteoporosis. However, the mechanism underlying this effect remains to be clarified. In this study, bovine LF (bLF) was first hydrolyzed by pepsin for 1 h, and the hydrolyzed mixture was freeze-dried and collected. The hydrolyzed mixture was then separated into 5 components (E1-E5), of which E3 had the greatest effect in promoting proliferation of osteoblasts (MC3T3-E1). Component E3 was further isolated into 21 components with preparative reversed phase HPLC, and the E3-15 component had maximal bioactivity. With HPLC-mass spectrometry and peptide sequencing, E3-15 was identified to contain amino acids 97 to 208 from the bLF N terminus. Then, E3-15 was divided into 6 different peptide segments (P1-P6), and the corresponding segments were generated by solid-phase synthesis. Only the P1 peptide (amino acids 97-122 from the N terminus of bLF) significantly promoted osteoblast proliferation. The bioactivity of P1 toward osteoblast cells and alkaline phosphatase activity were tested as a function of P1 concentration, and a nonlinear effect was observed.
Collapse
Affiliation(s)
- P Wen
- College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China
| | - W Zhang
- Beijing Laboratory of Food Quality and Safety, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China
| | - P Wang
- Beijing Laboratory of Food Quality and Safety, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China
| | - Y Zhang
- College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China
| | - W Zhang
- College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China
| | - Y Zhao
- Department of Grain Science and Industry, Kansas State University, Manhattan 66506.
| | - H Guo
- College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China; Beijing Laboratory of Food Quality and Safety, Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
| |
Collapse
|
|
11
|
Hu J, Huang J, Xu H, Wang Y, Li C, Wen P, You X, Zhang X, Pan G, Li Q, Zhang H, He J, Wu H, Jiang L, Wang H, Liu Y, Wan J. Rice stripe virus suppresses jasmonic acid-mediated resistance by hijacking brassinosteroid signaling pathway in rice. PLoS Pathog 2020; 16:e1008801. [PMID: 32866183 PMCID: PMC7485985 DOI: 10.1371/journal.ppat.1008801] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 09/11/2020] [Accepted: 07/12/2020] [Indexed: 01/23/2023] Open
Abstract
Rice stripe virus (RSV) is one of the most destructive viral diseases affecting rice production. However, so far, only one RSV resistance gene has been cloned, the molecular mechanisms underlying host-RSV interaction are still poorly understood. Here, we show that increasing levels or signaling of brassinosteroids (BR) and jasmonic acid (JA) can significantly enhance the resistance against RSV. On the contrary, plants impaired in BR or JA signaling are more susceptible to RSV. Moreover, the enhancement of RSV resistance conferred by BR is impaired in OsMYC2 (a key positive regulator of JA response) knockout plants, suggesting that BR-mediated RSV resistance requires active JA pathway. In addition, we found that RSV infection suppresses the endogenous BR levels to increase the accumulation of OsGSK2, a key negative regulator of BR signaling. OsGSK2 physically interacts with OsMYC2, resulting in the degradation of OsMYC2 by phosphorylation and reduces JA-mediated defense to facilitate virus infection. These findings not only reveal a novel molecular mechanism mediating the crosstalk between BR and JA in response to virus infection and deepen our understanding about the interaction of virus and plants, but also suggest new effective means of breeding RSV resistant crops using genetic engineering. Brassinosteroids (BR) and jasmonic acid (JA) play critical roles in responding to various stresses. However, the roles of BR and JA, particularly, the crosstalk between these two phytohormones in viral resistance is still very limited. In this work, we found that both BR and JA positively regulate RSV resistance, and JA pathway is necessary for BR-mediated RSV resistance in rice. RSV infection significantly inhibits the BR signaling pathway and increases the accumulation of OsGSK2. OsGSK2 interacts with and phosphorylates OsMYC2, resulting in the degradation of OsMYC2 and suppression of the JA-mediated RSV resistance response to facilitate virus infection. These findings revealed the molecular mechanism of crosstalk between the BR and JA in response to virus infection and deepen our understanding about the mechanism of RSV resistance.
Collapse
Affiliation(s)
- Jinlong Hu
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Jie Huang
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Haosen Xu
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Yongsheng Wang
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Chen Li
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Peizheng Wen
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Xiaoman You
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Xiao Zhang
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Gen Pan
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Qi Li
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Hongliang Zhang
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Jun He
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Hongming Wu
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Ling Jiang
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
| | - Haiyang Wang
- National Key Facility for Crop Gene Resources and Genetic Improvement, Institute of Crop Science, Chinese Academy of Agricultural Sciences, Beijing, People's Republic of China
| | - Yuqiang Liu
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
- * E-mail: (YL); (JW)
| | - Jianmin Wan
- State Key Laboratory of Crop Genetics and Germplasm Enhancement, Nanjing Agricultural University, Nanjing, People's Republic of China
- National Key Facility for Crop Gene Resources and Genetic Improvement, Institute of Crop Science, Chinese Academy of Agricultural Sciences, Beijing, People's Republic of China
- * E-mail: (YL); (JW)
| |
Collapse
|
|
12
|
Shen J, Lu Z, Wang JQ, Lan S, Zhang F, Hirata A, Chen MW, Wang XL, Wen P, Sun YH, Bai HY, Wang WH. Metallic Glacial Glass Formation by a First-Order Liquid-Liquid Transition. J Phys Chem Lett 2020; 11:6718-6723. [PMID: 32649204 DOI: 10.1021/acs.jpclett.0c01789] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The glacial phase, with an apparently glassy structure, can be formed by a first-order transition in some molecular-glass-forming supercooled liquids. Here we report the formation of metallic glacial glass (MGG) from the precursor of a rare-earth-element-based metallic glass via the first-order phase transition in its supercooled liquid. The excellent glass-forming ability of the precursor ensures the MGG to be successfully fabricated into bulk samples (with a minimal critical diameter exceeding 3 mm). Distinct enthalpy, structure, and property changes are detected between MGG and metallic glass, and the reversed "melting-like" transition from the glacial phase to the supercooled liquid is observed in fast differential scanning calorimetry. The kinetics of MGG formation is reflected by a continuous heating transformation diagram, with the phase transition pathways measured at different heating rates taken into account. The finding supports the scenario of liquid-liquid transition in metallic-glass-forming liquids.
Collapse
Affiliation(s)
- J Shen
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Z Lu
- Mathematics for Advanced Materials - Open Innovation Laboratory (MathAM-OIL), AIST, Sendai 980-8577, Japan
| | - J Q Wang
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
- Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China
| | - S Lan
- Herbert Gleiter Institute of Nanoscience, Nanjing University of Science and Technology, Nanjing 210094, China
- Department of Physics and Materials Science, City University of Hong Kong, Hong Kong, China
| | - F Zhang
- WPI- Advanced Institute for Materials Research (WPI-AIMR), Tohoku University, Sendai 980-8577, Japan
| | - A Hirata
- WPI- Advanced Institute for Materials Research (WPI-AIMR), Tohoku University, Sendai 980-8577, Japan
| | - M W Chen
- Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States
| | - X L Wang
- Department of Physics and Materials Science, City University of Hong Kong, Hong Kong, China
- City University of Hong Kong Shenzhen Research Institute, Shenzhen 518057, China
- Center for Advanced Structural Materials, City University of Hong Kong, Hong Kong China
| | - P Wen
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
| | - Y H Sun
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
- Songshan Lake Materials Laboratory, Dongguan, Guangdong 523808, China
| | - H Y Bai
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
- Songshan Lake Materials Laboratory, Dongguan, Guangdong 523808, China
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, China
| | - W H Wang
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
- School of Physical Sciences, University of Chinese Academy of Sciences, Beijing 100049, China
- Songshan Lake Materials Laboratory, Dongguan, Guangdong 523808, China
| |
Collapse
|
|
13
|
Li J, Han Q, Liu R, Wen P, Ji W, Pan L, Wang C, Zhao P, Liu H, Bao J. Effects of environment and breed on growth performance and meat quality of fattening pigs. Anim Welf 2020. [DOI: 10.7120/09627286.29.2.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Meat quality is not only influenced by breed but also rearing environment. The aim of this study was to evaluate the influence of different housing environments on growth performance, carcase traits, meat quality, physiological response pre-slaughter and fatty acid composition in two
pig breeds. A total of 120 growing pigs at 60–70 days of age were arranged in a 2 × 2 factorial design with the breeds (Duroc × Landrace × Large White [D × L × LW] and Duroc × Landrace × Min pig [D × L × M]) and environmental enrichment
(barren concrete floor or enriched with straw bedding) as factors. Each treatment was performed in triplicate with ten pigs per replicate. The pigs housed in the enriched environment exhibited a higher average daily gain, average daily feed intake, saturated fatty acid percentage and backfat
depth than the pigs reared in the barren environment. Plasma cortisol levels were lower and growth hormone higher in enriched compared to barren pens. The D × L × M pigs showed lower cooking loss compared with the D × L × LW pigs. Moreover, the D × L × M
pigs exhibited poor growth performance but had a better water-holding capacity. Only carcase traits and meat quality interaction effects were observed. We concluded that an enriched environment can reduce pre- slaughter stress and improve the growth performance of pigs and modulate the fatty
acid composition of pork products.
Collapse
|
|
14
|
Cappa F, Cini A, Pepiciello I, Petrocelli I, Inghilesi AF, Anfora G, Dani FR, Bortolotti L, Wen P, Cervo R. Female volatiles as sex attractants in the invasive population of Vespa velutina nigrithorax. J Insect Physiol 2019; 119:103952. [PMID: 31568763 DOI: 10.1016/j.jinsphys.2019.103952] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 09/18/2019] [Accepted: 09/26/2019] [Indexed: 06/10/2023]
Abstract
Due to its huge invasion potential and specialization in honeybee predation, the invasive hornet Vespa velutina nigrithorax represents a high-concern species under both an ecological and economical perspective. In light of the development of specific odorant attractants to be used in sustainable control strategies, we carried out both behavioural assays and chemical analyses to investigate the possibility that, in the invasive population of V. velutina nigrithorax, reproductive females emit volatile pheromones to attract males, as demonstrated in a Chinese non-invasive population. We focused on the secretions produced by sternal and venom glands; because of the volatility and complexity of their composition, both of them could potentially allow an attraction and a species-specific response, decreasing therefore non-target species by-catches. Results of chemical analyses and behavioural assays showed that venom volatiles, although population-specific, are unlikely candidates as male attractants since they do not differ in composition or in quantity between reproductive females and workers and do not attract males. Conversely, sternal gland secretion differs between female castes for the presence of some ketoacids exclusive of gynes already reported as sex pheromones for the non-invasive subspecies V. velutina auraria. Despite such a difference, males are attracted by the sternal gland secretion of both workers and gynes. These results provide a first step to understand the reproductive biology of V. velutina nigrithorax in its invasive range and to develop effective and sustainable management strategies for the species.
Collapse
Affiliation(s)
- Federico Cappa
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy.
| | - A Cini
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy; Centre for Biodiversity and Environment Research, University College London, Gower Street, London WC1E 6BT, UK
| | - I Pepiciello
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy
| | - I Petrocelli
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy
| | - A F Inghilesi
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy
| | - G Anfora
- Center Agriculture Food Environment (C3A), Università di Trento, Via E. Mach 1, 38010 San Michele a/A, Trento, Italy; Research and Innovation Centre, Fondazione Edmund Mach, Via E. Mach 1, 38010 San Michele a/A, Trento, Italy
| | - F R Dani
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy
| | - L Bortolotti
- CREA - Centro di ricerca Agricoltura e Ambiente, Unità di ricerca di apicoltura e bachicoltura (API), Via di Saliceto 80, 40128 Bologna, Italy
| | - P Wen
- Key Laboratory of Tropical Forest Ecology, Xishuangbanna Tropical Botanical Garden, Chinese Academy of Science, Qinsong Road 21, Panlong, Kunming, Yunnan 650223, China
| | - R Cervo
- Dipartimento di Biologia, Università di Firenze, Via Madonna del Piano, 50019 Sesto F.no (Firenze), Italy
| |
Collapse
|
|
15
|
Tabrizi S, Rahman R, Cagney D, Aizer A, Tanguturi S, Arvold N, Reardon D, Lee E, Nayak L, Rinne M, Ligon K, Wen P, Alexander B. Impact of Delay in Initiation of Radiation Therapy in Newly Diagnosed Glioblastoma Patients after Gross Total Resection. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
16
|
Zhao Y, Wang N, Wen P, Ouyang WB, Zhang FW, Qiu X, Liu Y, Zhao GZ, Xie YQ, Pan XB. [Safety and efficacy of percutaneous intervention for children with combined congenital heart abnormality solely guided by transthoracic echocardiography]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2018; 46:804-809. [PMID: 30369172 DOI: 10.3760/cma.j.issn.0253-3758.2018.10.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the safety and efficacy of percutaneous intervention of children with combined congenital heart abnormality solely guided by transthoracic echocardiography (TTE) . Methods: From September 2015 to June 2017, 21 children with combined congenital heart abnormality undergoing percutaneous interventional guided by TTE in Fuwai hospital were enrolled in our study, and the clinical data were retrospective analyzed. The atrial septal defect(ASD) closure, ventricular septal defect(VSD) closure, patent ductus arteriosus(PDA) closure or balloon pulmonary valvuloplasty were performed under the guidance of TTE. The procedural effect was evaluated by TTE after operation. The patients were followed up after discharged from the hospital. Results: The age was (37.3±11.6) months, and there were 9 male and 12 female patients. There were 4 cases with ASD and VSD, 6 cases with VSD and PDA, 6 cases with ASD and PDA, 2 cases with VSD and pulmonary stenosis, 3 cases with ASD and pulmonary stenosis. The operations were successfully performed in all patients. No one required extra X ray guidance or open heart surgery. The operation time was (44.6±7.5)min. All patients did not require blood transfusion, inotropic support, and analgesia. There were no complications such as peripheral vascular injury and pericardialeffusion after the operation. The length of hospital stay time was (3.5±0.6) days. All patients were recovered well. The follow-up was (17.6±5.2) months, and post-procedural conduction disturbances, residual shunts, occlude fall off, thrombosis, and new onset of valvular regurgitation were not observed in these patients. Conclusion: Percutaneous interventional of children with combined congenital heart abnormality solely guided by TTE is safe and effective, and the procedure can avoid the potential injuries of X ray and contrast agent.
Collapse
Affiliation(s)
- Y Zhao
- Department of Cardiothoracic Surgery, Dalian Children's Hospital, Dalian 116012, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
|
17
|
Dewan AK, Sowerby L, Jadeja S, Lian C, Wen P, Brown JR, Fisher DC, LeBoeuf NR. Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition. Clin Exp Dermatol 2018; 43:890-894. [PMID: 29851132 DOI: 10.1111/ced.13608] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Phosphoinositide 3-kinase (PI3K) inhibitors are a class of small-molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described. AIM To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. METHODS This was a retrospective analysis of patients receiving PI3K inhibitors referred to the Skin Toxicities Program in The Center for Cutaneous Oncology. RESULTS Three patients on PI3K inhibitors for treatment of malignancy developed diffuse erythroderma and keratoderma. Clinical and histopathological findings were consistent with pityriasis rubra pilaris (PRP)-like reactions. All patients improved with topical and oral corticosteroids, oral acitretin, and drug discontinuation. CONCLUSIONS PRP-like cutaneous eruptions may develop secondary to PI3K inhibition. Early dermatological evaluation of cutaneous toxicities to PI3K inhibitors as well as rapid initiation of disease-specific treatments may help keep patients on life-prolonging anti-cancer therapies.
Collapse
Affiliation(s)
- A K Dewan
- Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA
| | - L Sowerby
- Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA
| | - S Jadeja
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - C Lian
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - P Wen
- Department of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - J R Brown
- Chronic Lymphocytic Leukemia Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - D C Fisher
- Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - N R LeBoeuf
- Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA
| |
Collapse
|
|
18
|
Ding D, Zhao F, Huang YL, Li XL, Gong F, Yao ZC, Zhang BW, Yang ZY, Ma JM, Shen J, Wen P. [Effects of sural nerve nutrition vess els-supported flap for reconstruction of distal lower leg and ankle soft tissue defects]. Zhonghua Yi Xue Za Zhi 2018; 98:842-845. [PMID: 29609267 DOI: 10.3760/cma.j.issn.0376-2491.2018.11.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To observe the effects of sural nerve nutrition vessels-supported flap for reconstruction of distal lower leg and ankle soft tissue defects. Methods: From June 2014 to June 2017, 37 patients with calf distal and ankle soft tissue defect were repaired with sural nerve nutrition vessels-supported flap, of them 12 cases with calf distal soft tissue defect wounds and 25 cases with ankle soft tissue defect wounds.The scope of flaps was 9 cm×4 cm to 18 cm×9 cm, anti-infection, anti-freezing and dressing treatments were carried out after operation.The results of two-point discrimination among reexamination were recorded. Results: All the flaps survived without ulcer and effusion, only 1 flap for reconstruction of medial malleolus swelled and deactivated at the beginning while it recovered with proper dressings.During the follow-up periods, all the flaps kept favorable feelings, aspects and functions, and the two-point discrimination was 5 to 15 mm [averaged (11.2±1.7) mm]. Conclusion: Sural nerve nutrition vessels-supported flap brings significant effects with excellent safety and reliability in repairing calf and ankle soft tissue defects.
Collapse
Affiliation(s)
- D Ding
- Department of Hand and Foot Microsurgery for Reconstruction, the First Affiliated Hospital of Northwest University for Nationalities (the Affiliated Ningxia Peoples Hospital of Ningxia Medical University), Yinchuan 750003, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
19
|
Shi D, Arvold N, Aizer A, Norden A, Reardon D, Lee E, Nayak L, Dunn I, Golby A, Johnson M, Claus E, Chiocca A, Ligon K, Wen P, Alexander B. Salvage Re-Irradiation for Recurrent High-Grade Glioma and Comparison to Bevacizumab Alone. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
|
20
|
Nandu H, Kijewski MF, Dubey S, Belanger AP, Reardon D, Wen P, Kesari S, Horky L, Park M, Huang RY. P09.13 F-18 FLT PET and MRI as outcome predictors in glioblastomas following chemoradiation therapy. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
21
|
Zhou Y, Zhou M, Liao H, Rowland B, Arvold N, Reardon D, Wen P, Lin A, Huang RY. OS04.7 Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly Diagnosed Brain Mass and Suspected Recurrent Glioma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
22
|
Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol 2017; 111:60-65. [PMID: 28259296 DOI: 10.1016/j.critrevonc.2017.01.005] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Revised: 12/13/2016] [Accepted: 01/10/2017] [Indexed: 11/17/2022] Open
Abstract
Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ. In patients selected for clinical trials, median overall survival (OS) and progression-free survival (PFS) with this regimen is 15-17 months and 6-7 months, respectively. There have been various, largely unsuccessful attempts to improve on this standard of care. With the FDA approval of the tumor-treating fields (TTFields) device, Optune, for recurrent GBM (2011), and the more recent EF-14 interim trial results and approval for newly diagnosed GBM patients, several questions have arisen. A roundtable of experts was convened at the 2015 ASCO meeting to engage in an open conversation and debate of the EF-14 results presented at that meeting and their implications for neuro-oncology practice and clinical research. In October 2015, subsequent to the roundtable discussion, TTFields received FDA approval for newly diagnosed GBM.
Collapse
Affiliation(s)
- M Mehta
- Deputy Director, Miami Cancer Institute, and Chief of Radiation Oncology, Miami, Florida.
| | - P Wen
- Department of Neurology, Harvard University, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - R Nishikawa
- Japanese Society of Neuro-Oncology, Department of Neurosurgery, Saitama International Medical Center and University, Saitama, Japan
| | - D Reardon
- Center for Neuro-Oncology, Harvard Medical School, Boston, MA, United States
| | - K Peters
- Medicine, Duke University Medical Center, Durham, NC, United States
| |
Collapse
|
|
23
|
Abstract
We explore the correlation between a boson peak and structural relaxation in a typical metallic glass. Consistent with enthalpy recovery, a boson peak shows a memory effect in an aging-and-scan procedure. Single-step isothermal aging produces a monotonic decrease of enthalpy and boson peak intensity; for double-step isothermal aging, both enthalpy and boson peak intensity experience, coincidently, an incipient increase to a maximum and a subsequent decrease toward the equilibrium state. Our results indicate a direct link between slow structural relaxation and fast boson peak dynamics, which presents a profound understanding of the two dynamic behaviors in glass.
Collapse
Affiliation(s)
- P Luo
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| | - Y Z Li
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| | - H Y Bai
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| | - P Wen
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| | - W H Wang
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| |
Collapse
|
|
24
|
Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB, Xiao XZ. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci 2016; 20:866-872. [PMID: 27010143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To evaluate the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), adefovir dipivoxil (ADV) and entecavir (ETV) on decompensated hepatitis B virus-related cirrhosis. PATIENTS AND METHODS 1332 patients with decompensated hepatitis B virus-related cirrhosis were randomly assigned into 5 groups with different clinical treatment including LMV treatment, LdT treatment, ADV treatment, LMV+ADV treatment and ETV treatment. And then the liver function, Child-Pugh scores, sero-conversion of HBeAg/HBeAb, polymerase gene mutations, cost-effectiveness, incremental cost-effectiveness and side effects were investigated and further analyzed. RESULTS LMV, ADV, LdT, LMV+ADV and ETV were all effective on decreasing Child-Pugh scores and conversing negatively hepatitis B virus (HBV) DNA and HBeAg, whereas LMV+ADV and ETV more effective than LMV, ADV and LdT. HBV DNA polymerase genotypic mutations were rare in the 5 groups. The less mutation rate was found in the LMV+ADV and ETV group than in the LMV, ADV and LdT group. Compared to the cost-effectiveness and incremental cost-effectiveness ratio, ETV was the optimal selection, LMV+ADV was the alternative selection and LMV was the cheapest option. The side effects of the 5 plans were all rare and could be controlled. CONCLUSIONS LMV, ADV, LdT, LMV+ADV and ETV were all effective on treatment of decompensated hepatitis B virus-related cirrhosis whereas ETV and LMV+ADV were recommended.
Collapse
Affiliation(s)
- G-L Wang
- Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People's Republic of China.
| | | | | | | | | | | | | | | |
Collapse
|
|
25
|
Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, Yang YP, Xu YQ, Lv SW, Zhu YL. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian J Cancer 2015; 51 Suppl 3:e95-8. [PMID: 25818743 DOI: 10.4103/0019-509x.154084] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Angiogenesis plays an important role in the biology of ovarian cancer. The clinical efficacy and side effects of bevacizumab, the vascular endothelial growth factor inhibitor, on survival and toxicity in women with this ovarian cancer, was not conclusive. We performed this systematic review and meta-analysis in order to clarify the efficacy of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. MATERIALS AND METHODS We searched the electronic database of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and CNKI for clinical controlled trials of comparing bevacizumab combined with chemotherapy and chemotherapy alone in the treatment of ovarian cancer. The primary outcomes of eligible studies included median progression-free survival (PFS), overall survival (OS), and toxicities such as enterobrosis, hypertension, albuminuria, congestive heart failure (CHF), neutrophils, thrombosis, and bleeding. The Hazard ratio (HR) and relative risk were used for the meta-analysis and were expressed with 95% confidence intervals (CIs). All the statistical analyses were carried out by Stata 11.0 software (http://www.stata.com; Stata Corporation, College Station, TX, USA). RESULTS We included 5 studies with 1798 cases in the bevacizumab combined with the chemotherapy group and 1810 subjects in the chemotherapy alone group. The pooled results showed that bevacizumab + chemotherapy compared with chemotherapy alone can significant prolong the median PFS (HR, 0.64; 95% CI, 0.46-0.82; P < 0.05) but not the OS (HR, 0.84; 95% CI, 0.59-10.9; P > 0.05); the toxicity analysis showed that the enterobrosis, hypertension, albuminuria, neutrophils, thrombosis, and bleeding were significantly increased in the bevacizumab + chemotherapy group compared with chemotherapy alone (Pall < 0.05). But the CHF risk between the two groups was not statistical different (P > 0.05). CONCLUSION Bevacizumab combined with chemotherapy prolonged the median PFS in patients with ovarian cancer but also increase the risk of developing enterobrosis, hypertension, albuminuria, neutrophils, thrombosis, and bleeding.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Y L Zhu
- Department of Clinical Pharmacy, The Center Hospital of Jinhua City, Jinhua 321000, China
| |
Collapse
|
|
26
|
Zhu ZG, Li YZ, Wang Z, Gao XQ, Wen P, Bai HY, Ngai KL, Wang WH. Compositional origin of unusual β-relaxation properties in La-Ni-Al metallic glasses. J Chem Phys 2015; 141:084506. [PMID: 25173020 DOI: 10.1063/1.4893954] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The β-relaxation of metallic glasses (MGs) bears nontrivial connections to their microscopic and macroscopic properties. In an effort to elucidate the mechanism of the β-relaxation, we studied by dynamical mechanical measurements the change of its properties on varying the composition of La60Ni15Al25 in various ways. The properties of the β-relaxation turn out to be very sensitive to the composition. It is found that the isochronal loss peak temperature of β-relaxation, Tβ,peak, is effectively determined by the total (La + Ni) content. When Cu is added into the alloy to replace either La, Ni, or Al, the Tβ,peak increases with decrease of the (La + Ni) content. The trend is in accordance with data of binary and ternary MGs formed from La, Ni, Al, and Cu. Binary La-Ni MGs have pronounced β-relaxation loss peaks, well separated from the α-relaxation. In contrast, the β-relaxation is not resolved in La-Al and La-Cu MGs, showing up as an excess wing. For the ternary La-Ni-Al MGs, increase of La or Ni content is crucial to lower the Tβ,peak. Keeping the Al content fixed, increase of La content lowers the Tβ,peak further, indicating the more important role La plays in lowering Tβ,peak than Ni. The observed effects on changing the composition of La60Ni15Al25 lead to the conclusion that the properties of the β-relaxation are mainly determined by the interaction between the largest solvent element, La, and the smallest element, Ni. From our data, it is further deduced that La and Ni have high mobility in the MGs, and this explains why the β-relaxation in this La-based MGs is prominent and well resolved from the α-relaxation as opposed to Pd- and Zr-based MGs where the solvent and largest atoms, Pd and Zr, are the least mobile.
Collapse
Affiliation(s)
- Z G Zhu
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - Y Z Li
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - Z Wang
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - X Q Gao
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - P Wen
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - H Y Bai
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | - K L Ngai
- Dipartimento di Fisica, Università di Pisa, Largo B. Pontecorvo 3, I-56127 Pisa, Italy
| | - W H Wang
- Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| |
Collapse
|
|
27
|
Ding R, Feng L, He L, Chen Y, Wen P, Fu Z, Lin C, Yang S, Deng X, Zeng J, Sun G. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience 2015; 297:182-93. [PMID: 25849612 DOI: 10.1016/j.neuroscience.2015.03.065] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Revised: 03/19/2015] [Accepted: 03/29/2015] [Indexed: 10/23/2022]
Abstract
Hemoglobin (Hb) is a major constituent of blood and a potent mediator of oxidative or nitrative stress after intracerebral hemorrhage (ICH). Our previous study demonstrated that Hb could induce abundant peroxynitrite (ONOO(-)) formation in vivo, which may be involved in the blood-brain barrier (BBB) disruption, however, the drug intervention is absent and also the underlying mechanism. Using an experimental stroke model by injecting Hb into the caudate nucleus of male Sprague-Dawley rats, we assessed the role of ONOO(-) decomposition catalyst, 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinato iron(III) [FeTPPS] in the activation of MMP-9 and Hb-induced neurovascular injuries. 3-Nitrotyrosine (3-NT, as an index of ONOO(-) formation) and NF-κB expression was measured by western blot (WB) and immunohistochemistry (IHC)/immunofluorescence (IF). Activity of MMP was evaluated by in situ zymography. Neurovascular injury was assessed using zonula occludens-1 (ZO-1) by WB and IF, fibronectin (FN) and neuron-specific nuclear protein (NeuN) IHC. Perihematomal cell death was determined by TUNEL assay. Behavioral outcome was measured by modified neurological severity score (mNSS) test. At the injured striata, profuse 3-NT was produced and mainly expressed in neutrophils and microglia/macrophages. 3-NT formation significantly colocalized with nuclear factor-κB (NF-κB) expression. In situ zymography showed that gelatinase activity was mostly co-localized with neurons and blood vessel walls and partly with neutrophils and microglia/macrophages. Enhanced 3-NT production, NF-κB induction and MMP-9 activation were obviously reduced after FeTPPS treatment. Hb-induced injury to tight junction protein (ZO-1), basal lamina of FN-immunopositive microvasculature and neural cells was evidently ameliorated by FeTPPS. In addition, apoptotic cell numbers as well as behavioral deficits were also improved. The present study shows that the administration of the ONOO(-) decomposition catalyst FeTPPS protects against Hb-induced neurovascular injuries and improves neurological function, which possibly in part by suppressing MMP-9 activation.
Collapse
Affiliation(s)
- R Ding
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - L Feng
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - L He
- Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - Y Chen
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
| | - P Wen
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - Z Fu
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - C Lin
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - S Yang
- Department of Neurosurgery, Gaoqing Campus of Central Hospital of Zibo, Gaoqing People's Hospital, Gaoqing, Zibo 256300, Shandong, China
| | - X Deng
- Department of Neurosurgery, 999 Brain Hospital, Jinan University, Guangzhou 510510, China
| | - J Zeng
- The National Key Clinic Specialty, The Neurosurgery Institute of Guangdong Province, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - G Sun
- Department of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
|
28
|
Brenner A, Cohen Y, Vredenburgh J, Peters K, Blumenthal D, Bokstein F, Breitbart E, Bangio L, Sher N, Harats D, Wen P. NT-07 * PHASE 1-2 DOSE-ESCALATION STUDY OF VB-111, AN ANTI-ANGIOGENIC GENE THERAPY, AS MONOTHERAPY AND IN COMBINATION WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou265.7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
29
|
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu JJ, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G, Pan E, Kesari S, Yu J. AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou237.59] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
30
|
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou237.23] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
|
31
|
Lee E, Muzikansky A, Kesari S, Wong E, Fadul C, Reardon D, Norden A, Nayak L, Rinne M, Alexander B, Arvold N, Doherty L, LaFrankie D, Pulverenti J, Smith K, Gaffey S, Kenney A, Hammond S, Drappatz J, Wen P. SM-03 * A RANDOMIZED, PLACEBO-CONTROLLED PILOT TRIAL OF ARMODAFINIL FOR FATIGUE IN PATIENTS WITH GLIOMAS UNDERGOING RADIOTHERAPY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou277.3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
32
|
Huang R, Rahman R, Pope W, Ellingson B, Ballman K, Felton S, Anderson SK, Nayak L, Lee E, Abrey L, Galanis E, Reardon D, Cloughesy T, Wen P. NI-36 * VALIDATION OF RANO CRITERIA: CONTRIBUTION OF T2/FLAIR ASSESSMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou264.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
|
33
|
Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. AT-07 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou237.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
|
34
|
Chandra V, Ou Y, Evans J, Kalpathy-Cramer J, Dietrich J, Chi A, Wen P, Rosen B, Batchelor T, Gerstner E. AT-16 * PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou237.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
35
|
Gilbert M, Wen P, Schiff D, Aldape K. Highlights from the Literature. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
36
|
Liu W, Ye H, Tang B, Song Z, Sun Z, Wen P, Yang J. Profile of interdialytic ambulatory blood pressure in a cohort of Chinese patients. J Hum Hypertens 2014; 28:677-83. [PMID: 24919753 DOI: 10.1038/jhh.2014.41] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 04/19/2014] [Accepted: 05/01/2014] [Indexed: 01/20/2023]
Abstract
Management of hypertension is one of the fundamental interventions in dialysis patients. However, the profile of interdialytic blood pressure (BP) in Chinese dialysis patients remains elusive. We aim to investigate this issue as well as the effect of antihypertensive medication in this population. We performed 44-h ambulatory BP in 90 patients on maintenance hemodialysis. Patients were classified as 'dipping', 'non-dipping' or 'reverse-dipping' based on night/day ratio (N/D) of systolic BP on nondialysis day. The prevalence of blunted circadian BP pattern was strikingly high (92.2%), with more than half of the patients (55.6%) classified as reverse-dipping. There was a close association between high erythropoietin (EPO) dose used and deteriorated circadian rhythm. Patients in the dipping group also displayed a dipping state for heart rate (HR) compared with the other two groups (N/D of HR: 81.5 ± 6.6 vs 92.1 ± 6.0 and 91.3 ± 10.7, P=0.02). Only 26.7% patients had a controlled nocturnal BP. Patients with bedtime dosing had lower N/D of systolic BP compared with patients without (100.1 ± 7.0 vs 105.2 ± 7.1, P=0.01). Non-dipping and reverse-dipping are highly prevalent in Chinese patients. EPO use and autonomic dysfunction may contribute to the blunted circadian rhythm. More tightly control of nighttime BP is an urgent need and bedtime dosing may be beneficial.
Collapse
Affiliation(s)
- W Liu
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - H Ye
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - B Tang
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Z Song
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Z Sun
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - P Wen
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - J Yang
- Center for Kidney Disease, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| |
Collapse
|
|
37
|
Schiff D, Huse J, Wen P, Aldape K. Highlights from the Literature. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
38
|
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, de Groot J, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M, Apok V, Mills S, Soh C, Karabatsou K, Arimappamagan A, Arya S, Majaid M, Somanna S, Santosh V, Schaff L, Armentano F, Harrison C, Lassman A, McKhann G, Iwamoto F, Armstrong T, Yuan Y, Liu D, Acquaye A, Vera-Bolanos E, Diefes K, Heathcock L, Cahill D, Gilbert M, Aldape K, Arrillaga-Romany I, Ruddy K, Greenberg S, Nayak L, Avgeropoulos N, Avgeropoulos G, Riggs G, Reilly C, Banerji N, Bruns P, Hoag M, Gilliland K, Trusheim J, Bekaert L, Borha A, Emery E, Busson A, Guillamo JS, Bell M, Harrison C, Armentano F, Lassman A, Connolly ES, Khandji A, Iwamoto F, Blakeley J, Ye X, Bergner A, Dombi E, Zalewski C, Follmer K, Halpin C, Fayad L, Jacobs M, Baldwin A, Langmead S, Whitcomb T, Jennings D, Widemann B, Plotkin S, Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, Revil C, Lutiger B, Carpentier AF, Milojkovic-Kerklaan B, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, van Linde M, Awada A, Schellens J, Brandsma D, Brenner A, Sun J, Floyd J, Hart C, Eng C, Fichtel L, Gruslova A, Lodi A, Tiziani S, Bridge CA, Baldock A, Kumthekar P, Dilfer P, Johnston SK, Jacobs J, Corwin D, Guyman L, Rockne R, Sonabend A, Cloney M, Canoll P, Swanson KR, Bromberg J, Schouten H, Schaafsma R, Baars J, Brandsma D, Lugtenburg P, van Montfort C, van den Bent M, Doorduijn J, Spalding A, LaRocca R, Haninger D, Saaraswat T, Coombs L, Rai S, Burton E, Burzynski G, Burzynski S, Janicki T, Marszalek A, Burzynski S, Janicki T, Burzynski G, Marszalek A, Cachia D, Smith T, Cardona AF, Mayor LC, Jimenez E, Hakim F, Yepes C, Bermudez S, Useche N, Asencio JL, Mejia JA, Vargas C, Otero JM, Carranza H, Ortiz LD, Cardona AF, Ortiz LD, Jimenez E, Hakim F, Yepes C, Useche N, Bermudez S, Asencio JL, Carranza H, Vargas C, Otero JM, Bartels C, Quintero A, Restrepo CE, Gomez S, Bernal-Vaca L, Lema M, Cardona AF, Ortiz LD, Useche N, Bermudez S, Jimenez E, Hakim F, Yepes C, Mejia JA, Bernal-Vaca L, Restrepo CE, Gomez S, Quintero A, Bartels C, Carranza H, Vargas C, Otero JM, Carlo M, Omuro A, Grommes C, Kris M, Nolan C, Pentsova E, Pietanza M, Kaley T, Carrabba G, Giammattei L, Draghi R, Conte V, Martinelli I, Caroli M, Bertani G, Locatelli M, Rampini P, Artoni A, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Locatelli M, Caroli M, Rampini P, Chamberlain M, Raizer J, Soffetti R, Ruda R, Brandsma D, Boogerd W, Taillibert S, Le Rhun E, Jaeckle K, van den Bent M, Wen P, Chamberlain M, Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Kerloeguen Y, Guijarro A, Cloughsey T, Choi JH, Hong YK, Conrad C, Yung WKA, deGroot J, Gilbert M, Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D, Costa R, Lycette J, Gancher S, Cullen J, Winer E, Hochberg F, Sachs G, Jeyapalan S, Dahiya S, Stevens G, Peereboom D, Ahluwalia M, Daras M, Hsu M, Kaley T, Panageas K, Curry R, Avila E, Fuente MDL, Omuro A, DeAngelis L, Desjardins A, Sampson J, Peters K, Ranjan T, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman H, Bigner D, Gromeier M, Prust M, Kalpathy-Cramer J, Poloskova P, Jafari-Khouzani K, Gerstner E, Dietrich J, Fabi A, Villani V, Vaccaro V, Vidiri A, Giannarelli D, Piludu F, Anelli V, Carapella C, Cognetti F, Pace A, Flowers A, Flowers A, Killory B, Furuse M, Miyatake SI, Kawabata S, Kuroiwa T, Garciarena P, Anderson MD, Hamilton J, Schellingerhout D, Fuller GN, Sawaya R, Gilbert MR, Gilbert M, Pugh S, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Dignam J, Armstrong T, Wefel J, Brown P, Jaeckle K, Schiff D, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman E, Mehta M, Gill B, Yun J, Goldstein H, Malone H, Pisapia D, Sonabend AM, Mckhann GK, Sisti MB, Sims P, Canoll P, Bruce JN, Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M, Gore M, Hariharan S, Porta C, Bjarnason G, Bracarda S, Hawkins R, Oudard S, Zhang K, Fly K, Matczak E, Szczylik C, Grossman R, Ram Z, Hamza M, O'Brien B, Mandel J, DeGroot J, Han S, Molinaro A, Berger M, Prados M, Chang S, Clarke J, Butowski N, Hashimoto N, Chiba Y, Tsuboi A, Kinoshita M, Hirayama R, Kagawa N, Oka Y, Oji Y, Sugiyama H, Yoshimine T, Hawkins-Daarud A, Jackson PR, Swanson KR, Sarmiento JM, Ly D, Jutla J, Ortega A, Carico C, Dickinson H, Phuphanich S, Rudnick J, Patil C, Hu J, Iglseder S, Nowosielski M, Nevinny-Stickel M, Stockhammer G, Jain R, Poisson L, Scarpace L, Mikkelsen T, Kirby J, Freymann J, Hwang S, Gutman D, Jaffe C, Brat D, Flanders A, Janicki T, Burzynski S, Burzynski G, Marszalek A, Jiang C, Wang H, Jo J, Williams B, Smolkin M, Wintermark M, Shaffrey M, Schiff D, Juratli T, Soucek S, Kirsch M, Schackert G, Kakkar A, Kumar S, Bhagat U, Kumar A, Suri A, Singh M, Sharma M, Sarkar C, Suri V, Kaley T, Barani I, Chamberlain M, McDermott M, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Trojanec R, Hajduch M, Kneblova M, Ehrmann J, Kanner AA, Wong ET, Villano JL, Ram Z, Khatua S, Fuller G, Dasgupta S, Rytting M, Vats T, Zaky W, Khatua S, Sandberg D, Foresman L, Zaky W, Kieran M, Geoerger B, Casanova M, Chisholm J, Aerts I, Bouffet E, Brandes AA, Leary SES, Sullivan M, Bailey S, Cohen K, Mason W, Kalambakas S, Deshpande P, Tai F, Hurh E, McDonald TJ, Kieran M, Hargrave D, Wen PY, Goldman S, Amakye D, Patton M, Tai F, Moreno L, Kim CY, Kim T, Han JH, Kim YJ, Kim IA, Yun CH, Jung HW, Koekkoek JAF, Reijneveld JC, Dirven L, Postma TJ, Vos MJ, Heimans JJ, Taphoorn MJB, Koeppen S, Hense J, Kong XT, Davidson T, Lai A, Cloughesy T, Nghiemphu PL, Kong DS, Choi YL, Seol HJ, Lee JI, Nam DH, Kool M, Jones DTW, Jager N, Northcott PA, Pugh T, Hovestadt V, Markant S, Esparza LA, Bourdeaut F, Remke M, Taylor MD, Cho YJ, Pomeroy SL, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM, Krel R, Krutoshinskaya Y, Rosiello A, Seidman R, Kowalska A, Kudo T, Hata Y, Maehara T, Kumthekar P, Bridge C, Patel V, Rademaker A, Helenowski I, Mrugala M, Rockhill J, Swanson K, Grimm S, Raizer J, Meletath S, Bennett M, Nestor VA, Fink KL, Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Hammond S, Grimm S, Norden A, Beroukhim R, McCluskey C, Chi A, Batchelor T, Smith K, Gaffey S, Gerard M, Snodgras S, Raizer J, Wen P, Leeper H, Johnson D, Lima J, Porensky E, Cavaliere R, Lin A, Liu J, Evans J, Leuthardt E, Dacey R, Dowling J, Kim A, Zipfel G, Grubb R, Huang J, Robinson C, Simpson J, Linette G, Chicoine M, Tran D, Liubinas SV, D'Abaco GM, Moffat B, Gonzales M, Feleppa F, Nowell CJ, Gorelick A, Drummond KJ, Morokoff AP, O'Brien TJ, Kaye AH, Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R, Lupica K, Stevens G, Ly I, Hamilton S, Rostomily R, Rockhill J, Mrugala M, Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M, Burzynski S, Janicki T, Burzynski G, Marszalek A, Pachow D, Kliese N, Kirches E, Mawrin C, McNamara MG, Lwin Z, Jiang H, Chung C, Millar BA, Sahgal A, Laperriere N, Mason WP, Megyesi J, Salehi F, Merker V, Slusarz K, Muzikansky A, Francis S, Plotkin S, Mishima K, Adachi JI, Suzuki T, Uchida E, Yanagawa T, Watanabe Y, Fukuoka K, Yanagisawa T, Wakiya K, Fujimaki T, Nishikawa R, Moiyadi A, Kannan S, Sridhar E, Gupta T, Shetty P, Jalali R, Alshami J, Lecavalier-Barsoum M, Guiot MC, Tampieri D, Kavan P, Muanza T, Nagane M, Kobayashi K, Takayama N, Shiokawa Y, Nakamura H, Makino K, Hideo T, Kuroda JI, Shinojima N, Yano S, Kuratsu JI, Nambudiri N, Arrilaga I, Dunn I, Folkerth R, Chi S, Reardon D, Nayak L, Omuro A, DeAngelis L, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas J, Reimers HJ, Peereboom D, Rosenfeld S, Garst J, Ramnath N, Wing P, Zheng M, Urban P, Abrey L, Wen P, Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, Macdonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent M, Reardon DA, Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P, Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P, Bush NAO, Kesari S, Scott B, Ohno M, Narita Y, Miyakita Y, Arita H, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S, Okamura T, Kaneko S, Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire JP, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houllier C, Tanguy ML, Hoang-Xuan K, Omuro A, Abrey L, Raizer J, Paleologos N, Forsyth P, DeAngelis L, Kaley T, Louis D, Cairncross JG, Matasar M, Mehta J, Grimm S, Moskowitz C, Sauter C, Opinaldo P, Torcuator R, Ortiz LD, Cardona AF, Hakim F, Jimenez E, Yepes C, Useche N, Bermudez S, Mejia JA, Asencio JL, Carranza H, Vargas C, Otero JM, Lema M, Pace A, Villani V, Fabi A, Carapella CM, Patel A, Allen J, Dicker D, Sheehan J, El-Deiry W, Glantz M, Tsyvkin E, Rauschkolb P, Pentsova E, Lee M, Perez A, Norton J, Uschmann H, Chamczuck A, Khan M, Fratkin J, Rahman R, Hempfling K, Norden A, Reardon DA, Nayak L, Rinne M, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Wen P, Lee E, Ranjan T, Peters K, Vlahovic G, Friedman H, Desjardins A, Reveles I, Brenner A, Ruda R, Bello L, Castellano A, Bertero L, Bosa C, Trevisan E, Riva M, Donativi M, Falini A, Soffietti R, Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Nishikawa R, Dahr S, Hilton M, Garcia J, Cloughesy T, Sasaki H, Nishiyama Y, Yoshida K, Hirose Y, Schwartz M, Grimm S, Kumthekar P, Fralin S, Rice L, Drawz A, Helenowski I, Rademaker A, Raizer J, Schwartz K, Chang H, Nikolai M, Kurniali P, Olson K, Pernicone J, Sweeley C, Noel M, Sharma M, Gupta R, Suri V, Singh M, Sarkar C, Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T, Shih K, Chowdhary S, Rosenblatt P, Weir AB, Shepard G, Williams JT, Shastry M, Hainsworth JD, Singer S, Riely GJ, Kris MG, Grommes C, Sanders MWCB, Arik Y, Seute T, Robe PAJT, Leijten FSS, Snijders TJ, Sturla L, Culhane JJ, Donahue J, Jeyapalan S, Suchorska B, Jansen N, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Bartenstein P, Schnell O, Kreth FW, LaFougere C, Tonn JC, Taillandier L, Wittwer B, Blonski M, Faure G, De Carvalho M, Le Rhun E, Tanaka K, Sasayama T, Nishihara M, Mizukawa K, Kohmura E, Taylor S, Newell K, Graves L, Timmer M, Cramer C, Rohn G, Goldbrunner R, Turner S, Gergel T, Lacroix M, Toms S, Ueki K, Higuchi F, Sakamoto S, Kim P, Salgado MAV, Rueda AG, Urzaiz LL, Villanueva MG, Millan JMS, Cervantes ER, Pampliega RA, de Pedro MDA, Berrocal VR, Mena AC, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Hoekstra O, van Dongen G, Kaspers GJ, Schlamann A, von Bueren AO, Hagel C, Kramm C, Kortmann RD, Muller K, Friedrich C, Muller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber NU, Hau P, Kuehl J, Kortmann RD, von Bueren AO, Rutkowski S, von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Muller K, Pietsch T, Warmuth-Metz M, Kuehl J, Kortmann RD, Rutkowski S, Walker J, Tremont I, Armstrong T, Wang H, Jiang C, Wang H, Jiang C, Warren P, Robert S, Lahti A, White D, Reid M, Nabors L, Sontheimer H, Wen P, Yung A, Mellinghoff I, Lamborn K, Ramkissoon S, Cloughesy T, Rinne M, Omuro A, DeAngelis L, Gilbert M, Chi A, Batchelor T, Colman H, Chang S, Nayak L, Massacesi C, DiTomaso E, Prados M, Reardon D, Ligon K, Wong ET, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD, Elzinga G, Chung A, Wong ET, Wu W, Galanis E, Wen P, Das A, Fine H, Cloughesy T, Sargent D, Yoon WS, Yang SH, Chung DS, Jeun SS, Hong YK, Yust-Katz S, Milbourne A, Diane L, Gilbert M, Armstrong T, Zaky W, Weinberg J, Fuller G, Ketonen L, McAleer MF, Ahmed N, Khatua S, Zaky W, Olar A, Stewart J, Sandberg D, Foresman L, Ketonen L, Khatua S. NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2013; 15:iii98-iii135. [PMCID: PMC3823897 DOI: 10.1093/neuonc/not182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
|
39
|
Ahmed I, Biswas A, Krishnamurthy S, Julka P, Rath G, Back M, Huang D, Gzell C, Chen J, Kastelan M, Gaur P, Wheeler H, Badiyan SN, Robinson CG, Simpson JR, Tran DD, Rich KM, Dowling JL, Chicoine MR, Leuthardt EC, Kim AH, Huang J, Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS, Tieu M, Lovblom E, Macnamara M, Mason W, Rodin D, Tai E, Ubhi K, Laperriere N, Millar BA, Menard C, Perkins B, Chung C, Clarke J, Molinaro A, Phillips J, Butowski N, Chang S, Perry A, Costello J, DeSilva A, Rabbitt J, Prados M, Cohen AL, Anker C, Shrieve D, Hall B, Salzman K, Jensen R, Colman H, Farber O, Weinberg U, Palti Y, Fisher B, Chen H, Macdonald D, Lesser G, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary JP, Chakravarti A, Mehta M, Gupta T, Nair V, Epari S, Godasastri J, Moiyadi A, Shetty P, Juvekar S, Jalali R, Herrlinger U, Schafer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Kohnen R, Urbach H, Stummer W, Glas M, Houillier C, Ghesquieres H, Chabrot C, Soussain C, Ahle G, Choquet S, Faurie P, Bay JO, Vargaftig J, Gaultier C, Nicolas-Virelizier E, Hoang-Xuan K, Iskanderani O, Izar F, Benouaich-Amiel A, Filleron T, Moyal E, Iweha C, Jain S, Melian E, Sethi A, Albain K, Shafer D, Emami B, Kong XT, Green S, Filka E, Green R, Yong W, Nghiemphu P, Cloughesy T, Lai A, Mallick S, Biswas A, Roy S, Purkait S, Gupta S, Julka PK, Rath GK, Marosi C, Thaler J, Ay C, Kaider A, Reitter EM, Haselbock J, Preusser M, Flechl B, Zielinski C, Pabinger I, Miyatake SI, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Muragaki Y, Maruyama T, Iseki H, Akimoto J, Ikuta S, Nitta M, Maebayashi K, Saito T, Okada Y, Kaneko S, Matsumura A, Kuroiwa T, Karasawa K, Nakazato Y, Kayama T, Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Thurzo L, Zagonel V, Depenni R, Perry JR, Henslee-Downey J, Picard M, Reardon DA, Nambudiri N, Nayak L, LaFrankie D, Wen P, Ney D, Carlson J, Damek D, Blatchford P, Gaspar L, Kavanagh B, Waziri A, Lillehei K, Reddy K, Chen C, Rashed I, Melian E, Sethi A, Barton K, Anderson D, Prabhu V, Rusch R, Belongia M, Maheshwari M, Firat S, Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain M, Reardon DA, Wen P, Shapiro W, Gopal S, Judy K, Patel S, Mahapatra A, Shan J, Gupta D, Shih K, Bacha JA, Brown D, Garner WJ, Steino A, Schwart R, Kanekal S, Li M, Lopez L, Burris HA, Soderberg-Naucler C, Rahbar A, Stragliotto G, Song AJ, Kumar AMS, Murphy ES, Tekautz T, Suh JH, Recinos V, Chao ST, Spoor J, Korami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Sumrall A, Haggstrom D, Crimaldi A, Symanowski J, Giglio P, Asher A, Burri S, Sunkersett G, Khatib Z, Prajapati CM, Magalona EE, Mariano M, Sih IM, Torcuator R, Taal W, Oosterkamp H, Walenkamp A, Beerenpoot L, Hanse M, Buter J, Honkoop A, Boerman D, de Vos F, Jansen R, van der Berkmortel F, Brandsma D, Enting R, Kros J, Bromberg J, van Heuvel I, Smits M, van der Holt R, Vernhout R, van den Bent M, Weinberg U, Farber O, Palti Y, Wick W, Suarez C, Rodon J, Desjardins A, Forsyth P, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn M, Zach L, Guez D, Last D, Daniels D, Nissim O, Grober Y, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen Z, Mardor Y. MEDICAL RADIATION THERAPIES. Neuro Oncol 2013; 15:iii75-iii84. [PMCID: PMC3823894 DOI: 10.1093/neuonc/not179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
|
40
|
Arakawa Y, Fujimoto KI, Murata D, Nakamoto Y, Okada T, Miyamoto S, Bahr O, Harter PN, Weise L, You SJ, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E, Bahr O, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, Hattingen E, Carrillo J, Bota D, Handwerker J, Su LMY, Chen T, Stathopoulos A, Yu H, Chang JH, Kim EH, Kim SH, Mi, Yun J, Pytel P, Collins J, Choi Y, Lukas R, Nicholas M, Colen R, Jafrani R, Zinn P, Colen R, Ashour O, Zinn P, Colen R, Vangel M, Gutman D, Hwang S, Wintermark M, Jain R, Jilwan-Nicolas M, Chen J, Raghavan P, Holder C, Rubin D, Huang E, Kirby J, Freymann J, Jaffe C, Flanders A, Zinn P, Colen R, Ashour O, Zinn P, Colen R, Zinn P, Dahiya S, Statsevych V, Elson P, Xie H, Chao S, Peereboom D, Stevens G, Barnett G, Ahluwalia M, Daras M, Karimi S, Abrey L, Sanchez J, Beal K, Gutin P, Kaley T, Grommes C, Correa D, Reiner A, Briggs S, Omuro A, Verburg N, Hoefnagels F, Pouwels P, Boellaard R, Barkhof F, Hoekstra O, Wesseling P, Reijneveld J, Heimans J, Vandertop P, Zwinderman K, Hamer HDW, Elinzano H, Kadivar F, Yadav PO, Breese VL, Jackson CL, Donahue JE, Boxerman JL, Ellingson B, Pope W, Lai A, Nghiemphu P, Cloughesy T, Ellingson B, Pope W, Chen W, Czernin J, Phelps M, Lai A, Nghiemphu P, Liau L, Cloughesy T, Ellingson B, Leu K, Tran A, Pope W, Lai A, Nghiemphu P, Harris R, Woodworth D, Cloughesy T, Ellingson B, Pope W, Leu K, Chen W, Czernin J, Phelps M, Lai A, Nghiemphu P, Liau L, Cloughesy T, Ellingson B, Enzmann D, Pope W, Lai A, Nghiemphu P, Liau L, Cloughesy T, Eoli M, Di Stefano AL, Aquino D, Scotti A, Anghileri E, Cuppini L, Prodi E, Finocchiaro G, Bruzzone MG, Fujimoto K, Arakawa Y, Murata D, Nakamoto Y, Okada T, Miyamoto S, Galldiks N, Stoffels G, Filss C, Dunkl V, Rapp M, Sabel M, Ruge MI, Goldbrunner R, Shah NJ, Fink GR, Coenen HH, Langen KJ, Guha-Thakurta N, Langford L, Collet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, Bernaudin M, Abbas A, Ibazizene E, Barre L, Derlon JM, Guillamo JS, Harris R, Bookheimer S, Cloughesy T, Kim H, Pope W, Yang K, Lai A, Nghiemphu P, Ellingson B, Huang R, Rahman R, Hamdan A, Kane C, Chen C, Norden A, Reardon D, Mukundan S, Wen P, Jafrani R, Zinn P, Colen R, Jafrani R, Zinn P, Colen R, Jancalek R, Bulik M, Kazda T, Jensen R, Salzman K, Kamson D, Lee T, Varadarajan K, Robinette N, Muzik O, Chakraborty P, Barger G, Mittal S, Juhasz C, Kamson D, Barger G, Robinette N, Muzik O, Chakraborty P, Kupsky W, Mittal S, Juhasz C, Kinoshita M, Sasayama T, Narita Y, Kawaguchi A, Yamashita F, Chiba Y, Kagawa N, Tanaka K, Kohmura E, Arita H, Okita Y, Ohno M, Miyakita Y, Shibui S, Hashimoto N, Yoshimine T, Ronan LK, Eskey C, Hampton T, Fadul C, LaMontagne P, Milchenko M, Sylvester P, Benzinger T, Marcus D, Fouke SJ, Lupo J, Bian W, Anwar M, Banerjee S, Hess C, Chang S, Nelson S, Mabray M, Sanchez L, Valles F, Barajas R, Rubenstein J, Cha S, Miyake K, Ogawa D, Hatakeyama T, Kawai N, Tamiya T, Mori K, Ishikura R, Tomogane Y, Ando K, Izumoto S, Nelson S, Lieberman F, Lupo J, Viziri S, Nabors LB, Crane J, Wen P, Cote A, Peereboom D, Wen Q, Cloughesy T, Robins HI, Fisher J, Desideri S, Grossman S, Ye X, Blakeley J, Nonaka M, Nakajima S, Shofuda T, Kanemura Y, Nowosielski M, Wiestler B, Gobel G, Hutterer M, Schlemmer H, Stockhammer G, Wick W, Bendszus M, Radbruch A, Perreault S, Yeom K, Ramaswamy V, Shih D, Remke M, Luu B, Schubert S, Fisher P, Partap S, Vogel H, Poussaint TY, Taylor M, Cho YJ, Piludu F, Pace A, Fabi A, Anelli V, Villani V, Carapella C, Marzi S, Vidiri A, Pungavkar S, Tanawde P, Epari S, Patkar D, Lawande M, Moiyadi A, Gupta T, Jalali R, Rahman R, Akgoz A, You H, Hamdan A, Seethamraju R, Wen P, Young G, Rao A, Rao G, Flanders A, Ghosh P, Rao G, Martinez J, Rao A, Roh TH, Kim EH, Chang JH, Kushnirsky M, Katz J, Knisely J, Schulder M, Steinklein J, Rosen L, Warshall C, Nguyen V, Tiwari P, Rogers L, Wolansky L, Sloan A, Barnholtz-Sloan J, Tatsauka C, Cohen M, Madabhushi A, Rachinger W, Thon N, Haug A, Schuller U, Schichor C, Tonn JC, Tran A, Lai A, Li S, Pope W, Teixeira S, Harris R, Woodworth D, Nghiemphu P, Cloughesy T, Ellingson B, Villanueva-Meyer J, Barajas R, Mabray M, Barani I, Chen W, Shankaranarayanan A, Koon P, Cha S, Wen Q, Elkhaled A, Essock-Burns E, Molinaro A, Phillips J, Chang S, Cha S, Nelson S, Wolf D, Ye X, Lim M, Zhu H, Wang M, Quinones-Hinojosa A, Weingart J, Olivi A, van Zijl P, Laterra J, Zhou J, Blakeley J, Zakaria R, Das K, Sluming V, Bhojak M, Walker C, Jenkinson MD, (Tiger) Yuan S, Tao R, Yang G, Chen Z, Mu D, Zhao S, Fu Z, Li W, Yu J. RADIOLOGY. Neuro Oncol 2013; 15:iii191-iii205. [PMCID: PMC3823904 DOI: 10.1093/neuonc/not189] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
|
41
|
Jensen RL, Abraham S, Hu N, Jensen RL, Boulay JL, Leu S, Frank S, Vassella E, Vajtai I, von Felten S, Taylor E, Schulz M, Hutter G, Sailer M, Hench J, Mariani L, van Thuijl HF, Scheinin I, van Essen DF, Heimans JJ, Wesseling P, Ylstra B, Reijneveld JC, Borges AR, Larrubia PL, Marques JMB, Cerdan SG, Brastianos P, Horowitz P, Santagata S, Jones RT, McKenna A, Getz G, Ligon K, Palescandolo E, Van Hummelen P, Stemmer-Rachamimov A, Louis D, Hahn WC, Dunn I, Beroukhim R, Guan X, Vengoechea J, Zheng S, Sloan A, Chen Y, Brat D, O'Neill BP, Cohen M, Aldape K, Rosenfeld S, Noushmehr H, Verhaak RG, Barnholtz-Sloan J, Bahassi EM, Li YQ, Cross E, Li W, Vijg J, McPherson C, Warnick R, Stambrook P, Rixe O, Manterola L, Tejada-Solis S, Diez-Valle R, Gonzalez M, Jauregui P, Sampron N, Barrena C, Ruiz I, Gallego J, Delattre JY, de Munain AL, Mlonso MM, Saito K, Mukasa A, Nagae G, Aihara K, Takayanagi S, Aburatani H, Saito N, Kong XT, Fu BD, Du S, Hasso AN, Linskey ME, Bota D, Li C, Chen YS, Chen ZP, Kim CH, Cheong JH, Kim JM, Yelon NP, Jacoby E, Cohen ZR, Ishida J, Kurozumi K, Ichikawa T, Onishi M, Fujii K, Shimazu Y, Date I, Narayanan R, Ho QH, Levin BS, Maeder ML, Joung JK, Nutt CL, Louis DN, Thorsteinsdottir J, Fu P, Gehrmann M, Multhoff G, Tonn JC, Schichor C, Thirumoorthy K, Gordon N, Walston S, Patel D, Okamoto M, Chakravarti A, Palanichamy K, French P, Erdem L, Gravendeel L, de Rooi J, Eilers P, Idbaih A, Spliet W, den Dunnen W, Teepen J, Wesseling P, Smitt PS, Kros JM, Gorlia T, van den Bent M, McCarthy D, Cook RW, Oelschlager K, Maetzold D, Hanna M, Wick W, Meisner C, Hentschel B, Platten M, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, Schilling A, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M, Moren L, Johansson M, Bergenheim T, Antti H, Sulman EP, Goodman LD, Wani KM, DeMonte F, Aldape KD, Krischek B, Gugel I, Aref D, Marshall C, Croul S, Zadeh G, Nilsson CL, Sulman E, Liu H, Wild C, Lichti CF, Emmett MR, Lang FF, Conrad C, Alentorn A, Marie Y, Boisselier B, Carpetier C, Mokhtari K, Hoang-Xuan K, Capelle L, Delattre JY, Idbaih A, Lautenschlaeger T, Huebner A, McIntyre JB, Magliocco T, Chakravarti A, Hamilton M, Easaw J, Pollo B, Calatozzolo C, Vuono R, Guzzetti S, Eoli M, Silvani A, Di Meco F, Filippini G, Finocchiaro G, Joy A, Ramesh A, Smirnov I, Reiser M, Shapiro W, Mills G, Kim S, Feuerstein B, Gonda DD, Li J, McCabe N, Walker S, Goffard N, Wikstrom K, McLean E, Greenan C, Delaney T, McCarthy M, McDyer F, Keating KE, James IF, Harrison T, Mullan P, Harkin DP, Carter BS, Kennedy RD, Chen CC, Patel AS, Allen JE, Dicker DT, Rizzo K, Sheehan JM, Glantz MJ, El-Deiry WS, Salhia B, Ross JT, Kiefer J, Van Cott C, Metpally R, Baker A, Sibenaller Z, Nasser S, Ryken T, Ramanathan R, Berens ME, Carpten J, Tran NL, Bi Y, Pal S, Zhang Z, Gupta R, Macyszyn L, Fetting H, O'Rourke D, Davuluri RV, Ezrin AM, Moore K, Stummer W, Hadjipanayis CG, Cahill DP, Beiko J, Suki D, Prabhu S, Weinberg J, Lang F, Sawaya R, Rao G, McCutcheon I, Barker FG, Aldape KD, Trister AD, Bot B, Fontes K, Bridge C, Baldock AL, Rockhill JK, Mrugala MM, Rockne RR, Huang E, Swanson KR, Underhill HR, Zhang J, Shi M, Lin X, Mikheev A, Rostomily RC, Scheck AC, Stafford P, Hughes A, Cichacz Z, Coons SW, Johnston SA, Mainwaring L, Horowitz P, Craig J, Garcia D, Bergthold G, Burns M, Rich B, Ramkissoon S, Santagata S, Eberhart C, Ligon A, Goumnerova L, Stiles C, Kieran M, Hahn W, Beroukhim R, Ligon K, Ramkissoon S, Olausson KH, Correia J, Gafni E, Liu H, Theisen M, Craig J, Hayashi M, Haidar S, Maire C, Mainwaring LA, Burns M, Norden A, Wen P, Stiles C, Ligon A, Kung A, Alexander B, Tonellato P, Ligon KL. LAB-OMICS AND PROGNOSTIC MARKERS. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos231] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
|
42
|
Choi YJ, Gabikian P, Zhu F, Appelbaum DE, Wollmann RL, Lukas RV, Xu LW, Thomas RP, Lober RM, Nagpal S, Li G, Megyesi JF, Macdonald D, Chaudhary N, Berghoff AS, Spanberger T, Magerle M, Dinhof C, Woehrer A, Hackl M, Birner P, Widhalm G, Marosi C, Prayer D, Preusser M, Kamson DO, Juhasz C, Buth A, Kupsky WJ, Muzik O, Robinette NL, Barger GR, Mittal S, Kinoshita M, Hirayama R, Chiba Y, Kagawa N, Nonaka M, Kanemura Y, Kishima H, Nakajima S, Hatazawa J, Hashimoto N, Yoshimine T, Kim EH, Kim SH, Nowosielski M, Hutterer M, Putzer D, Iglseder S, Seiz M, Jacobs AH, Gobel G, Stockhammer G, Hutterer M, Nowosielski M, Putzer D, Iglseder S, Seiz M, Jacobs AH, Gobel G, Stockhammer G, Juhasz C, Buth A, Kamson DO, Kupsky WJ, Barger GR, Mittal S, Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, Hoffman C, Nass D, Spiegelmann R, Cohen ZR, Mardor Y, Mittal S, Buth A, Kupsky WJ, Kamson DO, Barger GR, Juhasz C, Perreault S, Lober RM, Zhang GH, Hershon L, Decarie JC, Yeom K, Vogel H, Partap S, Carret AS, Fisher PG, Colen RR, Changlai T, Sathyan P, Gutman D, Zinn P, Colen RR, Kovacs A, Zinn P, Jolesz F, Colen RR, Zinn P, Asthagiri A, Vasquez R, Butman J, Wu T, Morgan K, Brewer C, King K, Zalewski C, Jeffrey Kim H, Lonser R, Akbari H, Da X, Macyszyn L, Verma R, Wolf RL, Bilello M, Melhem ER, O'Rourke DM, Davatzikos C, Liu X, Madhankumar AB, Miller PA, Duck KA, Hafenstein S, Rizk E, Sheehan JM, Connor JR, Yang QX, Fouke SJ, Weinberger K, Kelsey M, Cholleti S, Politte D, Marcus D, Boyd A, Keogh B, Benzinger T, Milchenko M, Kim L, Prior F, Kim LM, Commean P, Boyd A, Milchenko M, Politte D, Chicoine M, Rich K, Benzinger T, Marcus D, Jost S, Fatterpekar G, Raz E, Knopp E, Gruber M, Parker E, Golfinos J, Zagzag D, Parker E, Fatterpekar G, Raz E, Narayana A, Johnson G, Placantonakis D, Zagzag D, Wen Q, Essock-Burns E, Li Y, Chang S, Nelson SJ, Li Y, Larson P, Chen A, Lupo JM, Kelley D, Chang S, Nelson SJ, Li Y, Lupo JM, Parvataneni R, Lamborn K, Cha S, Chang S, Nelson SJ, Jalbert LE, Elkhaled A, Phillips JJ, Williams C, Cha S, Berger MS, Chang SM, Nelson SJ, Damek DM, Ney DE, Borges MT, Colantoni W, Bert R, Huang R, Chen C, Mukundan S, Wen P, Norden A, Andre JB, Schmiedeskamp H, Thomas RP, Feroze A, Nagpal S, Zaharchuk G, Straka M, Recht L, Bammer R, Rockhill J, Mrugala M, Fink J, Rostomily R, Link J, Muzi M, Eary J, Krohn K, Perreault S, Lober RM, Partap S, Carret AS, Fisher FG, Ellingson BM, Pope WB, Boxerman JL, Harris RJ, Lai A, Nghiemphu PL, Jeyapalan S, Safran H, Kruse CA, Liau LM, Cloughesy TF, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Ellingson BM, Elkhaled A, Phillips J, Chang SM, Cha S, Nelson SJ. CLIN-RADIOLOGY. Neuro Oncol 2012; 14:vi120-vi128. [PMCID: PMC3488790 DOI: 10.1093/neuonc/nos236] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023] Open
|
|
43
|
Zhou SQ, Wen P, Fang L, Jiang L, Xiong M, Zhang FF, Yang JW. The association between RhEPO and FN expression in glomerular mesangial cells. Panminerva Med 2012; 54:205-209. [PMID: 22801437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM Erythropoietin (rhEPO) is increasingly being used in the treatment of anemia caused by miscellaneous reasons. The aim of our research is to investigate the effects of recombinant human erythropoietin (rhEPO) on cellular growth and fibronectin (FN) expression in glomerular mesangial cells. METHODS Western blot was used to detect the expression of FN induced by rhEPO (1, 10, 100 and 1000U/mL). In vivo studies, male CD-1 mice were administered rhEPO subcutaneously at a single dose of 1000U/Kg. The cellular hypertrophy was quantified by counting cell number and calculating the ratio of cell protein to cell number. RESULTS 1) Compared with the control group, the results of mesangial cells' growth stimulated by rhEPO were not significantly different; 2) RhEPO lead to hypertrophy of mesangial cells; 3) rhEPO induced FN expression of mesangial cell in a dose-dependent way. Compared to control, 100U/mL rhEPO enhanced the expression of FN significantly; 4) indirect immunofluorescence showed that rhEPO induced large amount deposition of FN in the intercellular space of mesangial cells; 5) in vivo studies, there were markedly increase of FN expression in mice received the injection of rhEPO. CONCLUSION RhEPO could up-regulated the expression of FN and induced glomerular mesangial cells hypertrophy. These results suggested rhEPO could induce dysfunction of renal glomerulus through its influence on the function of mesangial cells.
Collapse
Affiliation(s)
- S Q Zhou
- Emergency Department and Surgical Intensive Care Unit, Shanghai 10th People's Hospital Tongji University School of Medicine. Shanghai, China
| | | | | | | | | | | | | |
Collapse
|
|
44
|
Murray J, Braly E, Head H, Donahue D, Rush S, Stence N, Liu A, Kleinhenz J, Bison B, Pietsch T, von Hoff K, von Bueren A, Rutkowski S, Warmuth-Metz M, Jaspan T, Brisse H, Potepan P, Warmuth-Metz M, Berg F, Bison B, Pietsch T, Gerber N, Rutkowski S, Warmuth-Metz M, Sugiyama K, Kurisu K, Kajiwara Y, Takayasu T, Saito T, Hanaya R, Yamasaki F, Vicente J, Fuster-Garcia E, Tortajada S, Garcia-Gomez JM, Davies N, Natarajan K, Wilson M, Grundy RG, Wesseling P, Monleon D, Celda B, Robles M, Peet AC, Perret C, Boltshauser E, Scheer I, Kellenberger C, Grotzer M, Steffen-Smith E, Venzon D, Bent R, Baker E, Shandilya S, Warren K, Shih CS, West J, Ho C, Porter D, Wang Y, Saykin A, McDonald B, Arfanakis K, Warren K, Vezina G, Hargrave D, Poussaint TY, Goldman S, Packer R, Wen P, Pollack I, Zurakowski D, Kun L, Prados M, Kieran M, Eckel L, Keating G, Giannini C, Wetjen N, Patton A, Steffen-Smith E, Sarlls J, Pierpaoli C, Walker L, Venzon D, Bent R, Warren K, Perreault S, Lober R, Yeom K, Carret AS, Vogel H, Partap S, Fisher P, Gill SK, Wilson M, Davies NP, MacPherson L, Arvanitis TN, Peet AC, Davies N, Gill S, Wilson M, MacPherson L, Arvanitis T, Peet A, Hayes L, Jones R, Mazewski C, Aguilera D, Palasis S, Bendel A, Patterson R, Petronio J, Meijer L, Jaspan T, Grundy RGG, Walker DA, Robison N, Grant F, Treves ST, Bandopadhayay P, Manley P, Chi S, Zimmerman MA, Chordas C, Goumnerova L, Smith E, Scott M, Ullrich NJ, Poussaint T, Kieran M, Yang JC, Lightner DD, Khakoo Y, Wolden SL, Smee R, Zhao C, Spencer-Trotter B, Hallock A, Konski A, Bhambani K, Mahajan A, Jones J, Ketonen L, Paulino A, Ater J, Grosshans D, Dauser R, Weinberg J, Chintagumpala M, Dvir R, Elhasid R, Corn B, Tempelhoff H, Matceyevsky D, Makrin V, Shtraus N, Yavetz D, Constantini S, Gez E, Yu ES, Kim YJ, Park HJ, Kim HJ, Shin SH, Kim JH, Kim JY, Lee YK, Fiore MR, Sanne C, Mandeville HC, Saran FH, Greenspoon J, Duckworth J, Singh S, Scheinemann K, Whitton A, Gauvain K, Geller T, Elbabaa S, Dombrowski J, Wong K, Olch A, Davidson TB, Venkatramani R, Haley K, Zaky W, Dhall G, Finlay J, Bishop MW, Hummel TR, Leach J, Minturn J, Breneman J, Stevenson C, Wagner L, Sutton M, Miles L, Fouladi M, Goldman S. RADIOLOGY. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
|
45
|
Lee E, Batchelor T, Kaley T, Schiff D, Lassman A, Wong E, Mikkelsen T, Purow B, Drappatz J, Norden A, Beroukhim R, Weiss S, Alexander B, McCluskey C, Gerard M, Teulings L, Smith K, Muzikansky A, Wen P. Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s45.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
|
46
|
Hammond S, Drappatz J, Lee E, Muzikansky A, Weiss S, Kesari S, Wong E, Fadul C, Norden A, Beroukhim R, Alexander B, Ruland S, Ciampa A, Lafrankie D, Doherty L, McCluskey C, Smith K, Gerard M, Wen P. Interim Analysis of a Randomized Placebo-Controlled Pilot Trial of Armodafinil for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment (P07.104). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p07.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
|
47
|
Chheda M, Wen P, Hochberg F, Chi A, Drappatz J, Yang D, Eichler A, Beroukhim R, Norden A, Gerstner E, Batchelor T. Phase I Trial of Vandetanib Plus Sirolimus in Adults with Recurrent Glioblastoma (P04.180). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p04.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
|
48
|
Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BGM, Sonneveld P, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26:595-608. [PMID: 22193964 DOI: 10.1038/leu.2011.346] [Citation(s) in RCA: 189] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions.
Collapse
|
|
49
|
Locasale JW, Melman T, Song SS, Yang X, Swanson KD, Cantley LC, Asara JM, Wong ET, Adams S, Braidy N, Teo C, Guillemin G, Philippe M, Carole C, David T, Eric G, Isabelle NM, de Paula Andre M, Marylin B, Olivier C, L'Houcine O, Dominique FB, Leukel P, Seliger C, Vollmann A, Jachnik B, Bogdahn U, Hau P, Liu X, Kumar VS, McPherson CM, Chow L, Kendler A, Dasgupta B, Piya S, White E, Klein S, Jiang H, Lang F, Alfred Yung WK, Gomez-Manzano C, Fueyo J, Vartanian A, Guha A, Fenton KE, Abdelwahab M, Scheck AC, Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Iwanami A, Tanaka K, Gini B, DeJesus J, Lisiero DD, Huang T, Prins R, Wen P, Robbins HI, Prados M, DeAngelis L, Mellinghoff I, Mehta M, James CD, Chakravarti A, Cloughesy T, Tontonoz P, Mischel P, Phillips J, Mukherjee J, Cowdrey C, Wiencke J, Pieper RO, Bachoo R, Marin-Valencia I, Cho S, Rakheja D, Hatanpaa K, Mashimo T, Vemireddy V, Kapur P, Good L, Sun X, Pascual J, Takahashi M, Togao O, Raisanen J, Maher EA, DeBerardinis R, Malloy C, Maher EA, Bachoo R, Marin-Valencia I, Hatanpaa K, Choi C, Mashimo T, Raisanen J, Mathews D, Pascual J, Madden C, Mickey B, Malloy C, DeBerardinis R, Mukherjee J, Zheng S, Phillips J, Cowdrey C, Ronen S, Wiencke J, Pieper RO, Park I, Jalbert LE, Ito M, Ozawa T, James CD, Phillips JJ, Vigneron DB, Pieper RO, Ronen SM, Nelson SJ. METABOLIC PATHWAYS. Neuro Oncol 2011; 13:iii69-iii72. [PMCID: PMC3199168 DOI: 10.1093/neuonc/nor153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
|
50
|
Cao Y, Zou SM, Zhang KT, Lu N, Liu Y, Feng L, Wen P, Han NJ, Lin DM. Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. Histol Histopathol 2011; 26:491-6. [PMID: 21360442 DOI: 10.14670/hh-26.491] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Epithelioid hemangioendothelioma (EHE) is a low-to-intermediate-grade vascular tumor that occurs in many organs, and epithelioid angiosarcoma (EA) is a subtype of angiosarcoma that is associated with high-grade malignancy. These two types of tumors have different forms of biological behavior. Pulmonary epithelioid hemangioendothelioma (PEH) and epithelioid angiosarcoma (PEA) are both very rare, and genetic studies on them are extremely limited. We examined and compared the cytogenetic characteristics of these two types of lung tumors in two patients utilizing the Array-Comparative Genomic Hybridization (Array-CGH) method. Considerable differences in the cytogenetic characteristics were observed between the two types of tumors. Small fragment gains (<10 MB) were dominant in PEH, whereas large fragment gains and deletions (>10 MB) were dominant in PEA. Some large fragment alterations, such as gains in chromosomes 19q and 19p, and deletions in chromosomes 9p and 13q, involved over half of a chromosome arm. PEH and PEA showed great cytogenetic differences; therefore, further genetic studies on these two types of tumors are warranted.
Collapse
Affiliation(s)
- Y Cao
- Department of Pathology, Plastic Surgery Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | | | | | | | | | | | | | | | | |
Collapse
|